Factors associated with readmissions in women participating in screening programs and treated for breast cancer: a retrospective cohort study.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
05 Dec 2019
Historique:
received: 11 07 2019
accepted: 28 11 2019
entrez: 7 12 2019
pubmed: 7 12 2019
medline: 5 3 2020
Statut: epublish

Résumé

We aimed to identify the risk factors associated with early, late and long-term readmissions in women diagnosed with breast cancer participating in screening programs. We performed a multicenter cohort study of 1055 women aged 50-69 years participating in Spanish screening programs, diagnosed with breast cancer between 2000 and 2009, and followed up to 2014. Readmission was defined as a hospital admission related to the disease and/or treatment complications, and was classified as early (< 30 days), late (30 days-1 year), or long-term readmission (> 1 year). We used logistic regression to estimate the adjusted odds ratios (aOR), and 95% confidence intervals (95% CI) to explore the factors associated with early, late and long-term readmissions, adjusting by women's and tumor characteristics, detection mode, treatments received, and surgical and medical complications. Among the women included, early readmission occurred in 76 (7.2%), late readmission in 87 (8.2%), long-term readmission in 71 (6.7%), and no readmission in 821 (77.8%). Surgical complications were associated with an increased risk of early readmissions (aOR = 3.62; 95%CI: 1.27-10.29), and medical complications with late readmissions (aOR = 8.72; 95%CI: 2.83-26.86) and long-term readmissions (aOR = 4.79; 95%CI: 1.41-16.31). Our results suggest that the presence of surgical or medical complications increases readmission risk, taking into account the detection mode and treatments received. Identifying early complications related to an increased risk of readmission could be useful to adapt the management of patients and reduce further readmissions. ClinicalTrials.govIdentifier: NCT03165006. Registration date: May 22, 2017 (Retrospectively registered).

Sections du résumé

BACKGROUND BACKGROUND
We aimed to identify the risk factors associated with early, late and long-term readmissions in women diagnosed with breast cancer participating in screening programs.
METHODS METHODS
We performed a multicenter cohort study of 1055 women aged 50-69 years participating in Spanish screening programs, diagnosed with breast cancer between 2000 and 2009, and followed up to 2014. Readmission was defined as a hospital admission related to the disease and/or treatment complications, and was classified as early (< 30 days), late (30 days-1 year), or long-term readmission (> 1 year). We used logistic regression to estimate the adjusted odds ratios (aOR), and 95% confidence intervals (95% CI) to explore the factors associated with early, late and long-term readmissions, adjusting by women's and tumor characteristics, detection mode, treatments received, and surgical and medical complications.
RESULTS RESULTS
Among the women included, early readmission occurred in 76 (7.2%), late readmission in 87 (8.2%), long-term readmission in 71 (6.7%), and no readmission in 821 (77.8%). Surgical complications were associated with an increased risk of early readmissions (aOR = 3.62; 95%CI: 1.27-10.29), and medical complications with late readmissions (aOR = 8.72; 95%CI: 2.83-26.86) and long-term readmissions (aOR = 4.79; 95%CI: 1.41-16.31).
CONCLUSION CONCLUSIONS
Our results suggest that the presence of surgical or medical complications increases readmission risk, taking into account the detection mode and treatments received. Identifying early complications related to an increased risk of readmission could be useful to adapt the management of patients and reduce further readmissions.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.govIdentifier: NCT03165006. Registration date: May 22, 2017 (Retrospectively registered).

Identifiants

pubmed: 31805926
doi: 10.1186/s12913-019-4789-3
pii: 10.1186/s12913-019-4789-3
pmc: PMC6896282
doi:

Banques de données

ClinicalTrials.gov
['NCT03165006']

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

940

Subventions

Organisme : Instituto de Salud Carlos III
ID : PS09/01153
Organisme : Instituto de Salud Carlos III
ID : PI12/00387
Organisme : Instituto de Salud Carlos III
ID : PI11/01296
Organisme : Instituto de Salud Carlos III
ID : PI15/00098
Organisme : Instituto de Salud Carlos III
ID : RD12/0001/0015
Organisme : Instituto de Salud Carlos III
ID : RD16/0001/0013
Organisme : Instituto de Salud Carlos III
ID : RD12/0001/0007

Références

Gac Sanit. 2019 Sep - Oct;33(5):434-441
pubmed: 30031657
Int J Cancer. 2017 Aug 15;141(4):671-677
pubmed: 28457023
Gland Surg. 2017 Feb;6(1):14-26
pubmed: 28210548
J Med Screen. 2012;19 Suppl 1:5-13
pubmed: 22972806
Med Care. 2006 Nov;44(11):972-81
pubmed: 17063128
BMJ. 2010 Mar 23;340:c1241
pubmed: 20332505
Br J Cancer. 2017 Mar 14;116(6):828-839
pubmed: 28183141
Breast Dis. 2015;35(4):221-31
pubmed: 26397768
Support Care Cancer. 2016 Jan;24(1):311-317
pubmed: 26062923
Ann Oncol. 2008 Apr;19(4):614-22
pubmed: 18024988
Breast Cancer Res. 2015 May 01;17:63
pubmed: 25928287
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Am Coll Surg. 2007 Feb;204(2):193-200
pubmed: 17254922
J Natl Cancer Inst. 2011 Apr 6;103(7):585-97
pubmed: 21350218
Ann Oncol. 2010 May;21 Suppl 3:iii43-51
pubmed: 20427360
J Oncol Pract. 2015 Mar;11(2):120-5
pubmed: 25585617
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
J Natl Cancer Inst. 2006 Aug 16;98(16):1108-17
pubmed: 16912263
Sci Rep. 2018 Jun 11;8(1):8882
pubmed: 29892094
Eur J Surg Oncol. 2015 Oct;41(10):1417-22
pubmed: 26253193
J Am Coll Surg. 2004 May;198(5):707-16
pubmed: 15110803
JAMA Surg. 2015 Nov;150(11):1042-9
pubmed: 26244543
Br J Cancer. 2013 Jun 11;108(11):2205-40
pubmed: 23744281
Breast Cancer Res. 2014 Jan 10;16(1):R3
pubmed: 24410848
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
World J Surg. 2018 May;42(5):1396-1402
pubmed: 29380006
Breast J. 2015 Sep-Oct;21(5):526-32
pubmed: 26104795
Breast Cancer Res Treat. 2015 Nov;154(2):403-15
pubmed: 26531756
Plast Reconstr Surg. 2014 Aug;134(2):193e-201e
pubmed: 25068340

Auteurs

Carme Miret (C)

Preventive Medicine and Public Health Training Unit PSMar-UPF-ASPB, Parc de Salut Mar, Agència de Salut Pública de Barcelona, Pompeu Fabra University, Barcelona, Spain.
Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain.

Laia Domingo (L)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, 08003, Barcelona, Spain. ldomingo@parcdesalutmar.cat.
Research Network on Health Services in Chronic Diseases (REDISSEC), Av. de Monforte de Lemos, 5, 28029, Madrid, Spain. ldomingo@parcdesalutmar.cat.

Javier Louro (J)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Av. de Monforte de Lemos, 5, 28029, Madrid, Spain.

Teresa Barata (T)

General Directorate of Health Care Programs, Canary Islands Health Service, C/ Juan XXIII,13, 35005, Las Palmas de Gran Canaria, Spain.

Marisa Baré (M)

Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Av. de Monforte de Lemos, 5, 28029, Madrid, Spain.
Cancer Screening and Clinical Epidemiology, Corporació Sanitària Parc Taulí, 08208, Sabadell, Spain.

Joana Ferrer (J)

Department of Radiology, Hospital de Santa Caterina, C/ Dr. Castany, s/n, 17190 Salt, Girona, Spain.

Maria Carmen Carmona-García (MC)

Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Catalan Institute of Oncology, C/ Sol, 15, 17004, Girona, Spain.
Girona Biomedical Research Institute (IDIBGI), C/ Dr Castany s/n, 17190 Salt, Girona, Spain.
Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Dr Josep Trueta, Av. França, S/N, 17007, Girona, Spain.

Xavier Castells (X)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Av. de Monforte de Lemos, 5, 28029, Madrid, Spain.

Maria Sala (M)

Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, 08003, Barcelona, Spain.
Research Network on Health Services in Chronic Diseases (REDISSEC), Av. de Monforte de Lemos, 5, 28029, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH